In recent months, there has been growing concern about the potential risks associated with blood transfusions using blood products derived from individuals who have received mRNA vaccines. A recent article published on Preprints.org calls attention to these risks and proposes specific measures to address them.
The article highlights the increasing volume of evidence that has come to light regarding the potential dangers of using blood products from those who have suffered from long COVID and recipients of genetic vaccines, including mRNA vaccines. It argues that there is a need for medical professionals to be aware of these risks and take appropriate measures to mitigate them.
One of the main concerns raised in the article is the possibility of post-vaccination syndrome and its consequences. The authors suggest that transfusions of blood products from individuals who have received genetic vaccines may increase the likelihood of adverse reactions in the recipients. They argue that specific tests and testing methods should be implemented to identify any potential risks before transfusions take place.
The authors also propose regulations to ensure the safety of blood transfusions involving blood products from individuals who have received mRNA vaccines. These regulations would aim to minimize the potential risks and provide guidelines for healthcare professionals to follow when considering transfusion options.
It is important to note that this article is based on a preprint, meaning it has not yet undergone peer review. However, it raises important points for consideration and highlights the need for further research on this topic. As the COVID-19 vaccination campaign continues worldwide, it is crucial that the potential risks associated with blood transfusions using blood products from vaccinated individuals are thoroughly investigated.
